HomeCryoLife Inc.CryoLife Receives CE Mark for E-nya Thoracic Stent Graft

CryoLife Receives CE Mark for E-nya Thoracic Stent Graft

CryoLife, Inc. announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending thoracic aorta, including thoracic aortic aneurysms and dissections.  The E-nya thoracic stent-graft will be manufactured at the Company’s facility in Hechingen, Germany.

“We are pleased to have received CE Mark for the E-nya thoracic stent graft system, our next generation low profile solution for patients with aortic disease.  The E-nya system was designed to give physicians more options and control while treating both simple and challenging anatomies, and will be one of the most versatile grafts on the market,” said Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife.  We are excited to bring this product to the European market, further enhancing our position as the leader in the growing EU aortic repair market.”

Aortic aneurysms and dissections make up the largest portion of thoracic aortic disease which is an estimated $600 million global market.  The vast majority of patients with thoracic aortic disease are treated with minimally invasive endovascular stent-grafts.

E-nya builds upon JOTEC’s experience in the thoracic endovascular aortic repair (TEVAR) market and increases the number of options to treat a broader range of patients.  The system offers both bare spring and covered proximal configurations with tip capture technology, enhancing the control and predictability during deployment while achieving optimal outcomes.  The lower profile graft material leverages JOTEC’s expertise in textile manufacturing and is designed for both flexibility in conformance and long-term durability.

“E-nya is the next generation stent-graft from JOTEC/CryoLife to treat thoracic aortic pathologies.  The combination of the new delivery system with the completely redesigned stent-graft improves flexibility, allowing surgeons to treat a broader range of patients and more complex pathologies,” said Prof. Alexander Oberhuber, Chief of Vascular Surgery, University Hospital of Münster, Germany.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy